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Abstract
Background: Many plants of boreal forest of Quebec have been used by Native Americans to treat a variety of
microbial infections. However, the antiviral activities of these plants have been seldom evaluated on cellular models
to validate their in vitro efficiencies. In this study, Cornus canadensis L. (Cornaceae), a plant used in Native American
traditional medicine to treat possible antiviral infections, has been selected for further examination.
Methods: The plant was extracted by decoction and infusion with water, water/ethanol 1:1 and ethanol to obtain
extracts similar to those used by Native Americans. The effects of the extracts were tested on herpes simplex virus
type-1 (HSV-1) using a plaque reduction assay. Moreover, bioassay-guided fractionation was achieved to isolate
bioactive compounds.
Results: Water/ethanol 1:1 infusion of C. canadensis leaves were the most active extracts to inhibit virus absorption
with EC50 of about 9 μg mL−1, whereas for direct mode, both extraction methods using water or water/ethanol 1:1
as solvent were relatively similar with EC50 ranging from 11 to 17 μg mL−1. The fractionation led to the identification
of active fractions containing hydrolysable tannins. Tellimagrandin I was found the most active compound with an
EC50 of 2.6 μM for the direct mode and 5.0 μM for the absorption mode.
Conclusion: Altogether, the results presented in this work support the antiviral activity of Cornus canadensis used in
Native American traditional medicine.
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Background
Herpes simplex virus type-1 (HSV-1) is one of the most
common infections in the human population. The preva-
lence in the world’s population aged between 0 and 49 years
old was estimated in 2012 at 3.7 billion people (67%) [1].
HSV-1 is an encapsulated DNA virus of the family Herpes-
viridae. It is responsible for self-limiting infections causing
vesicular lesions of the oral (herpes labialis) or genital
mucosa (genital herpes) [1]. Outbreaks of HSV are prob-
ably triggered by immune deficiency, emotional stress and
UV radiation [2]. Despite available treatments, recurrent
oral or genital herpes significantly impairs the quality of life
[3, 4]. HSV-1 can also infect the cornea and nervous sys-
tem, thereby causing encephalitis, corneal blindness and
peripherical nervous system disorders [5, 6]. Encephalitis
caused by HSV-1 is the most sporadic fatal encephalitis
worldwide with significant morbidity and mortality. Over
seventy percent of childrens with HSV-1 encephalitis die
or have permanent neurological impairment even with
antiviral therapy [5, 6]. Acyclovir, an antiviral agent, is
currently the preferred drug to treat herpes infection. This
deoxyguanosine analogue inhibits HSV-1 replication by
targeting the viral DNA polymerase [7]. However, acyclovir,
and related drugs, can induce resistance and cause side-
effects as acute renal insufficiency and neurotoxicity [8, 9].
Therefore, new antiviral agents active against HSV-1 must
be discovered. Interestingly, plants are an important source
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of biologically active compounds. About 25% of all new ac-
tive substances discovered between 1981 and 2014 are nat-
ural products or are derived from natural products [10].
Moreover, many plant-derived compounds possess an anti-
HSV-1 activity [11].
The herpes virus has been present in Native American
populations for thousands of years [12]. Cornus canaden-
sis was used by Native American to treat some general
symptoms caused by HSV-1 infections such as sores
(Thompson), pain (Abnaki, Delaware) and fevers (Iro-
quois, Costanoan) [13]. However, no study has been con-
ducted to evaluate their in vitro antiviral activity. In this
report, leaf extracts from Cornus canadensis L. (Corna-
ceae), used by Native Americans in traditional medicine,
have been selected to evaluate their anti-HSV-1 potential.
Methods
General
Optical rotations were obtained at the sodium D line
(589 nm) on a Jasco DIP-360 digital polarimeter. NMR
spectra were recorded at 292 K on a Bruker Avance 400 op-
erating at 400.13 MHz for 1H and 100.61 MHz for 13C and
using a 5 mm QNP probe with a z-gradient coil. All spectra
were acquired in methanol-d4 unless otherwise specified
and chemical shifts were reported in ppm (δ) relative to
TMS. Preparative HPLC were first carried out with an Agi-
lent 1100 series on a Zorbax Eclipse XDB-C18 column
(4.6 × 250 mm, 5 μm) and then scaled-up on a Zorbax
PrepHT Eclipse XDB-C18 column (21.2 × 250 mm, 7 μm).
Low-pressure liquid chromatography (LPLC) was carried
out on a Büchi Sepacore flash system consisting of a con-
trol unit (C-620), two pump modules (C-605), a UV de-
tector (C-635), and a fraction collector (C-660). Reagent
grade dichloromethane (DCM), methanol (MeOH), hex-
anes (Hex) and ethyl acetate (EtOAc) were purchased from
VWR International (Ville Mont-Royal, Québec, Canada)
and used without further purification for the extraction and
separation of compounds 1–19. The adsorbents used for
open column chromatography (CC) were Diaion HP20
(VWR International, Québec, Canada), silica gel Ultra Pure
(40–63 μm, Silicycle, Québec, Canada) and C18 reversed
phase silica gel Ultra Pure (carbon 11%, 40–63 μm, Silicycle,
Québec, Canada). TLC was performed on silica gel 60 F254
glass plates (250 μm layer thickness, Silicycle, Québec,
Canada). Reversed phase TLC was carried out on Merck
RP-18 F254s glass plates. The TLC plates were sprayed with
5% aq. H2SO4 followed by 1% vanillin in ethanol and heated
at 110 °C for 5 min. TLC spots were visualized by inspec-
tion of the plates under visible light [14].
Plant material
All plant specimens were harvested between May and July
2008, or in June 2012, in the “Forêt d’Enseignement et de
Recherche Simoncouche” of the Réserve Faunique des
Laurentides, Québec, Canada (48° 14′ 40″ N, 71° 15′ 15″
W). The plants were identified at the Université du Québec
à Chicoutimi by M. Patrick Nadeau. A voucher specimen
(QFA0610437) was deposited at the Herbarium Louis-
Marie of Université Laval, Québec, Canada. The leaves and
the stems were dried at room temperature for one week
after which they were grounded and stored at −18 °C until
processed.
Extracts preparation
To mimic the classical uses by the Native Americans, two
types of extraction were performed including decoction
and infusion. Water, water/ethanol 1:1 and ethanol were
used as solvents. Firstly, plant powder (10 g) was boiled in
100 mL of solvent for one hour and the obtained decoc-
tion was filtered. The same procedure was repeated three
times with the same plant material and the results of the
three successive extractions were combined. Secondly,
boiling solvent was added to 10 g of powdered plant and
mixed for one hour at room temperature. The resulting
infusion was filtered and the procedure was repeated three
times on the same plant material, as described above.
Crude ethanol extracts were concentrated under vacuum
and subsequently lyophilized while crude water extracts
were only lyophilized.
Bioassay-guided fractionation
For the bioassay-guided fractionation, a large scale extrac-
tion was performed. C. canadensis powder (3 594 g) was
refluxed in 50% aq. EtOH (43 L). After filtration, the resi-
dues were extracted two other times with 2 × 29 L of 50%
aq. EtOH. The extraction solutions were combined and
concentrated in vacuo. The solution was partitioned with
CHCl3 (4 × 50 L). Both layers were separated and evapo-
rated in vacuo yielding a green CHCl3 fraction (28.5 g,
0.8%) and a brown aqueous fraction (1098.7 g, 30.6%).
The brown gum (550 g) was suspended in water (5 L) and
extracted with n-BuOH (3 × 2.5 L). Both fractions were
evaporated in vacuo yielding a brown water fraction
(514.4 g, 28.6%) and a brown n-BuOH fraction (35.6 g,
2.0%). Each of these extracts (CHCl3, n-BuOH and H2O)
were tested for anti-HSV-1 activity.
The n-BuOH fraction (35 g) was separated by CC on Dia-
ion with a step gradient of H2O and MeOH as follow: H2O
and MeOH 10% afforded fractions F1 (6.2 g) and F2 (4.6 g),
MeOH 30 to 50% afforded fractions F3 (2.4 g) and F4
(8.8 g), MeOH 80% afforded fraction F5 (6.9 g) and MeOH
100% afforded fraction F6 (2.0 g). Fraction F4 was separated
by LPLC on silica gel with DCM-MeOH-H2O (200:48:7→
40:48:7) as the eluent followed by MeOH containing 2%
acetic acid. The resulting fractions were gathered according
to their TLC profiles providing seven fractions: F4.1
(361 mg), F4.2 (548 mg), F4.3 (399 mg), F4.4 (1079 mg),
F4.5 (2312 mg), F4.6 (1121 mg) and F4.7 (2207 mg).
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Fraction F5 was separated by CC on silica gel with DCM-
MeOH (6:1→ 0:1) affording ten fractions: F5.1 (35 mg),
F5.2 (66 mg), F5.3 (189 mg), F5.4 (388 mg), F5.5 (425 mg),
F5.6 (1099 mg), F5.7 (1047 mg), F5.8 (433 mg), F5.9
(817 mg) and F5.10 (2602 mg). Fraction 4.1 was purified by
preparative HPLC (H2O-CH3CN, 9:1→ 7:3 in 30 min)
affording compound 8 (4.2 mg) and 10 (0.7 mg). Fraction
F4.4 was purified by preparative HPLC (H2O-CH3CN,
19:1→ 16:4 in 40 min) affording compound 2 (1.7 mg), 3
(3.2 mg), 4 (5.3 mg) and 6 (1.2 mg). Fraction F4.5 was puri-
fied by preparative HPLC (H2O-CH3CN, 19:1→ 16:4 in
40 min) affording compound 1 (1.0 mg), 4 (4.9 mg), 5
(9.3 mg), 6 (5.0 mg), 7 (1.1 mg), and 9 (15.5 mg). Fraction
5.3 was purified by preparative HPLC (H2O-CH3CN,
9:1→ 6:4 in 30 min) affording compound 8 (13.5 mg) and
18 (3.3 mg). Fraction 5.4 was analyzed by analytical HPLC
(H2O-CH3CN-HCOOH, 950:50:1→ 800:200:1 in 20 min)
and was shown to contain pure 11. Fraction 5.5 was
purified by preparative HPLC (H2O-CH3CN, 8:2 for 5 min
then 8:2→ 7:3 in 20 min) yielding a mixture of compounds
16 and 19 (1.7 mg), and pure 13 (11.3 mg), 15 (2.1 mg),
and 17 (2.0 mg). Finally, fraction 5.6 was purified by pre-
parative HPLC (H2O-CH3CN, 9:1→ 7:3 in 30 min) yielding
compound 10 (27.7 mg), 11 (1.3 mg), 12 (7.7 mg), 13
(2.8 mg), 14 (3.0 mg), and 15 (2.5 mg). All of these isolates
were identified as: 1,6-di-O-galloyl-β-D-glucopyranose (1)
[15], 1,2,3-tri-O-galloyl-β-D-glucopyranose (2) [16], 1,2,6-
tri-O-galloyl-β-D-glucopyranose (3) [17], 1,2,3,6-tetra-O-
galloyl-β-D-glucopyranose (4) [15], 1,2,3,4,6-penta-O-gal-
loyl-β-D-glucopyranose (5) [18], tellimagrandin I (6), tellima-
grandin II (7) [19], ethyl gallate (8) [20], caffeic acid (9)
[21], astragalin (10), isoquercetin (11) [22], trifolin (12)
[23], kaempferol 3-O-β-D-xylopyranoside (13) [24], reinu-
trin (14) [25], juglanin (15), avicularin (16) [26], juglalin
(17) [27], benzyl 2-O-β-glucopyranosyl-2,6- hydroxybenzo-
ate (18) [28] and byzantionoside B (19) [29].
Characterization of isolated compounds
1,6-Di-O-galloyl-β-D-glucopyranose (1): Brown amorph-
ous solid; 1H NMR (400 MHz, CD3OD) δ: 7.12 (2H, s,
H-2,6I), 7.07 (2H, s, H-2,6VI), 5.68 (1H, d, J = 6.4 Hz, H-
1), 4.54 (1H, br d, J = 12.0 Hz, H-6a), 4.39 (1 H, dd, J =
12.0, 4.9 Hz, H-6b), 3.71 (1H, m, H-5), 3.51 (3H, m, H-2,
H-3, H-4); 13C NMR (100 MHz, CD3OD) δ: 168.34 (s,
C-7VI), 167.03 (s, C-7I), 146.56 (s, C-3,5VI), 146.52 (s, C-
3,5I), 140.51 (s, C-4I), 139.93 (s, C-4VI), 121.31 (s, C-1VI),
120.61 (s, C-1I), 110.61 (d, C-2,6I), 110.22 (d, C-2,6VI),
95.98 (d, C-1), 78.07 (d, C-3), 76.51 (d, C-5), 74.14 (d, C-
2), 71.23 (d, C-4), 64.47 (t, C-6).
1,2,3-Tri-O-galloyl-β-D-glucopyranose (2): Brown
amorphous solid; [α]D
25 +33.3° (c = 0.04, MeOH); 1H
NMR (400 MHz, CD3OD) δ: 7.03 (2H, s, H-2,6
III),
7.02 (2H, s, H-2,6I), 6.91 (2H, s, H-2,6II), 6.05 (1H, d,
J = 8.3 Hz, H-1), 5.53 (1H, t, J = 9.5 Hz, H-3), 5.41
(1H, dd, J = 9.9, 8.2 Hz, H-2), 3.92 (1H, br d, J =
12.9 Hz, H-6a), 3.88 (1H, t, J = 9.7 Hz, H-4), 3.80
(1H, dd, J = 12.2, 4.6 Hz, H-6b), 3.69 (1H, m, H-5);
13C NMR (100 MHz, CD3OD) δ: 167.83 (s, C-7
III),
167.20 (s, C-7II), 166.42 (s, C-7I), 146.56 (s, C-4I),
146.39 (s, C-4III), 146.36 (s, C-4II), 140.68 (s, C-3,5I),
140.20 (s, C-3,5II), 139.99 (s, C-3,5III), 121.09 (s, C-
1III), 120.51 (s, C-1II), 120.00 (s, C-1I), 110.56 (d, C-
2,6I), 110.43 (d, C-2,6III), 110.39 (d, C-2,6II), 93.92 (d,
C-1), 79.07 (d, C-5), 76.79 (d, C-3), 72.45 (d, C-2),
69.35 (d, C-4), 61.89 (t, C-6).
1,2,6-Tri-O-galloyl-β-D-glucopyranose (3): Brown
amorphous solid; [α]D
25 −80.7° (c = 0.09, MeOH); 1H NMR
(400 MHz, CD3OD) δ: 7.11 (2H, s, H-2,6
VI), 7.05 (2H, s,
H-2,6II), 7.01 (2H, s, H-2,6I), 5.93 (1H, d, J = 8.4 Hz, H-1),
5.22 (1H, t, J = 9.0 Hz, H-2), 4.57 (1H, br d, J = 12.0 Hz, H-
6a), 4.47 (1H, dd, J = 12.1, 4.6 Hz, H-6b), 3.84 (1H, m, H-
5), 3.83 (1H, m, H-3), 3.67 (1H, t, J = 9.3 Hz, H-4); 13C
NMR (100 MHz, CD3OD) δ: 168.30 (s, C-7
VI), 167.62 (s,
C-7II), 166.54 (s, C-7I), 146.54 (s, C-4VI), 146.51 (s, C-4I),
146.45 (s, C-4II), 140.63 (s, C-3,5I), 140.08 (s, C-3,5II),
139.95 (s, C-3,5VI), 121.30 (s, C-1VI), 121.08 (s, C-1II),
120.02 (s, C-1I), 110.60 (d, C-2,6I), 110.41 (d, C-2,6II),
110.24 (d, C-2,6VI), 94.15 (d, C-1), 76.65 (d, C-5), 76.00 (d,
C-3), 74.31 (d, C-2), 71.40 (d, C-4), 64.26 (t, C-6).
1,2,3,6-Tetra-O-galloyl-β-D-glucopyranose (4): Brown
amorphous solid; [α]D
25 +37.4° (c = 0.18, MeOH); 1H
NMR (400 MHz, CD3OD) δ: 7.13 (2H, s, H-2,6
VI), 7.04
(2H, s, H-2,6III), 7.03 (2H, s, H-2,6I), 6.94 (2H, s, H-
2,6II), 6.11 (1H, d, J = 8.3 Hz, H-1), 5.59 (1H, dd, J = 9.6,
9.0 Hz, H-3), 5.45 (1H, dd, J = 9.9, 8.3 Hz, H-2), 4.62
(1H, dd, J = 12.4, 1.9 Hz, H-6a), 4.53 (1H, dd, J = 12.1,
4.3 Hz, H-6b), 4.03 (1H, ddd, J = 10.0, 4.3, 1.9 Hz, H-5),
3.97 (1H, dd, J = 9.7, 8.8 Hz, H-4); 13C NMR (100 MHz,
CD3OD) δ: 168.19 (s, C-7
VI), 167.74 (s, C-7III), 167.20 (s,
C-7II), 166.34 (s, C-7I), 146.54 (s, C-4VI), 146.54 (s, C-4I),
146.38 (s, C-4III), 146.35 (s, C-4II), 140.75 (s, C-3,5I),
140.24 (s, C-3,5II), 140.03 (s, C-3,5III), 140.00 (s, C-3,5VI),
121.23 (s, C-1VI), 120.98 (s, C-1III), 120.41 (s, C-1II),
119.84 (s, C-1I), 110.61 (d, C-2,6I), 110.43 (d, C-2,6III),
110.40 (d, C-2,6II), 110.24 (d, C-2,6VI), 93.93 (d, C-1),
76.65 (d, C-5), 76.49 (d, C-3), 72.39 (d, C-2), 69.66 (d, C-
4), 64.00 (t, C-6).
1,2,3,4,6-Penta-O-galloyl-β-D-glucopyranose (5): Brown
amorphous solid; [α]D
25 +21.8° (c = 0.29, MeOH); 1H NMR
(400 MHz, CD3OD) δ: 7.12 (2H, s, H-2
VI), 7.06 (2H, s, H-
2I), 6.98 (2H, s, H-2IV), 6.95 (2H, s, H-2II), 6.90 (2H, s, H-
2III), 6.25 (1H, d, J = 8.3 Hz, H-1), 5.92 (1H, t, J = 9.7 Hz,
H-3), 5.63 (1H, t, J = 9.7 Hz, H-4), 5.59 (1H, dd, J = 9.8,
8.4 Hz, H-2), 4.52 (1H, br d, J = 11.1 Hz, H-6a), 4.42 (1H,
m, H-5), 4.39 (1H, m, H-6b); 13C NMR (100 MHz,
CD3OD) δ: 167.94 (C-7
VI), 167.31 (C-7III), 167.03 (C-7II),
166.93 (C-7IV), 166.23 (C-7I), 146.57 (C-3I), 146.49 (C-
3VI), 146.46 (C-3IV), 146.39 (C-3II), 146.30 (C-3III), 140.78
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(C-4I), 140.37 (C-4IV), 140.32 (C-4II), 140.14 (C-4III),
140.02 (C-4VI), 121.05 (C-1VI), 120.37 (C-1III), 120.25 (C-
1II), 120.21 (C-1IV), 119.73 (C-1I), 110.62 (C-2I), 110.47
(C-2IV), 110.41 (C-2II), 110.38 (C-2III), 110.34 (C-2VI),
93.83 (C-1), 74.44 (C-5), 74.13 (C-3), 72.20 (C-2), 69.80
(C-4), 63.13 (C-6).
Tellimagrandin I (2,3-di-O-galloyl-4,6-hexahydroxydi-
phenoyl-β-D-glucopyranose, 6): Brown amorphous solid;
[α]D
25 +70.5° (c = 0.16, MeOH); 1H NMR (400 MHz,
CD3OD) δ: α-anomer (60%): 7.01 (2H, s, H-2,6
II), 6.92
(2H, s, H-2,6III), 6.60 (1H, s, H-2VI), 6.49 (1H, s, H-2IV),
5.83 (1H, t, J = 10.0 Hz, H-3), 5.49 (1H, d, J = 3.8 Hz, H-1),
5.32 (1H, dd, J = 12.7, 6.6 Hz, H-6), 5.12 (1H, t, J = 9.9 Hz,
H-4), 5.09 (1H, dd, J = 9.4, 4.5 Hz, H-2), 4.64 (1H, dd, J =
10.1, 6.8 Hz, H-5), 3.82 (1H, d, J = 12.8 Hz, H-6); β-
anomer (40%): 6.99 (2H, s, H-2,6II), 6.89 (2H, s, H-2,6III),
6.60 (1H, s, H-2VI), 6.45 (1H, s, H-2IV), 5.59 (1H, t, J =
9.7 Hz, H-3), 5.35 (1H, dd, J = 12.8, 6.6 Hz, H-6), 5.19 (1H,
dd, J = 9.6, 8.1 Hz, H-2), 5.14 (1H, t, J = 9.9 Hz, H-4), 4.96
(1H, d, J = 8.1 Hz, H-1), 4.21 (1H, dd, J = 9.8, 6.4 Hz, H-5),
3.90 (1H, d, J = 13.0 Hz, H-6); 13C NMR (100 MHz,
CD3OD) δ: α anomer: 169.78 (s, C-7
VI), 169.32 (s, C-7IV),
167.94 (s, C-7III), 167.48 (s, C-7II), 146.41 (s, C-4II), 146.22
(s, C-4III), 145.94 (s, C-4IV), 145.87 (s, C-4VI), 144.82 (2×,
s, C-5IV and C-5VI), 140.16 (s, C-3,5II), 139.93 (s, C-3,5III),
137.62 (2×, s, C-3IV and C-3VI), 126.36 (s, C-1IV), 125.96
(s, C-1VI), 120.79 (s, C-1III), 120.60 (s, C-1II), 116.71 (s, C-
6VI), 116.42 (s, C-6IV), 110.46 (d, C-2,6III), 110.42 (d, C-
2,6II), 108.66 (d, C-2VI), 108.26 (d, C-2IV), 91.80 (d, C-1),
73.61 (d, C-2), 72.00 (d, C-3), 71.99 (d, C-4), 67.61 (d, C-
5), 64.29 (t, C-6); β anomer: 169.68 (s, C-7VI), 169.24 (s,
C-7IV), 167.70 (s, C-7III), 167.12 (s, C-7II), 146.38 (s, C-4II),
146.19 (s, C-4III), 145.93 (s, C-4IV), 145.89 (s, C-4VI),
144.82 (2×, s, C-5IV and C-5VI), 140.01 (s, C-3,5II), 139.95
(s, C-3,5III), 137.62 (2×, s, C-3IV and C-3VI), 126.32 (s, C-
1IV), 125.89 (s, C-1VI), 120.93 (s, C-1III), 120.59 (s, C-1II),
116.66 (s, C-6VI), 116.46 (s, C-6IV), 110.48 (d, C-2,6III),
110.37 (d, C-2,6II), 108.62 (d, C-2VI), 108.24 (d, C-2IV),
97.12 (d, C-1), 74.82 (d, C-2), 74.33 (d, C-3), 71.69 (d, C-
4), 71.59 (d, C-5), 64.22 (t, C-6).
Tellimagrandin II (1,2,3-tri-O-galloyl-4,6-hexahydroxydi-
phenoyl-β-D-glucopyranose, 7): Brown amorphous solid;
[α]D
25 +32.1° (c = 0.08, MeOH); 1H NMR (400 MHz,
CD3OD) δ: 7.05 (2H, s, H-2,6
I), 6.95 (2H, s, H-2,6II), 6.91
(2H, s, H-2,6III), 6.61 (1H, s, H-2VI), 6.48 (1H, s, H-2IV),
6.11 (1H, d, J = 8.3 Hz, H-1), 5.76 (1H, t, J = 9.7 Hz, H-3),
5.54 (1H, dd, J = 9.3, 8.4 Hz, H-2), 5.39 (1H, dd, J = 13.3,
6.5 Hz, H-6a), 5.23 (1H, t, J = 9.9 Hz, H-4), 4.43 (1H, dd, J
= 10.1, 6.4 Hz, H-5), 3.92 (1H, d, J = 13.3 Hz, H-6b); 13C
NMR (100 MHz, CD3OD) δ: 169.59 (s, C-7
VI), 169.24 (s,
C-7IV), 167.57 (s, C-7III), 166.92 (s, C-7II), 166.19 (s, C-7I),
146.62 (s, C-4I), 146.43 (s, C-4II), 146.27 (s, C-4III), 145.86
(s, C-4IV), 145.82 (s, C-4VI), 145.17 (s, C-5IV), 145.15 (s, C-
5VI), 140.82 (s, C-3,5I), 140.33 (s, C-3,5II), 140.11 (s, C-
3,5III), 137.80 (s, C-3IV), 137.78 (s, C-3VI), 126.24 (s, C-1IV),
126.24 (s, C-1VI), 120.45 (s, C-1III), 120.32 (s, C-1II), 119.74
(s, C-1I), 116.87 (d, C-6VI), 116.69 (d, C-6IV), 110.61 (d, C-
2,6I), 110.53 (d, C-2,6III), 110.41 (d, C-2,6II), 108.59 (d, C-
2VI), 108.21 (d, C-2IV), 94.2 (d, C-1), 74.07 (d, C-3), 73.64
(d, C-5), 72.47 (d, C-2), 71.28 (d, C-4), 63.73 (t, C-6).
Ethyl gallate (8): Brown amorphous solid; 1H NMR
(400 MHz, CD3OD) δ: 7.05 (2H, s, H-2,6), 4.27 (2H, q, J
= 7.1 Hz, H-1′), 1.35 (3 H, t, J = 7.1 Hz, H-2′); 13C NMR
(100 MHz, CD3OD) δ: 168.58 (s, C-7), 146.50 (s, C-3,5),
139.71 (s, C-4), 121.77 (s, C-1), 110.00 (d, C-2,6), 61.71
(t, C-1′), 14.66 (q, C-2′).
Caffeic acid (9): White amorphous solid; 1H NMR
(400 MHz, CD3OD) δ: 7.59 (1H, d, J = 15.9 Hz, H-7),
7.05 (1H, d, J = 2.0 Hz, H-2), 6.95 (1H, dd, J = 8.3,
2.0 Hz, H-6), 6.77 (1H, d, J = 8.2 Hz, H-5), 6.30 (1H, d, J
= 15.9 Hz, H-8); 13C NMR (100 MHz, CD3OD) δ: 169.05
(s, C-9), 149.65 (s, C-4), 147.26 (d, C-7), 146.84 (s, C-3),
127.76 (s, C-1), 123.04 (d, C-6), 116.52 (d, C-5), 115.20
(d, C-2), 114.88 (d, C-8).
Astragalin (kaempferol 3-O-β-D-glucopyranoside, 10):
Yellow amorphous solid; [α]D
25 −36.3° (c = 0.43, MeOH);
1H NMR (400 MHz, CD3OD) δ: 8.05 (2H, d, J = 8.7 Hz,
H-2′,6′), 6.88 (2H, d, J = 8.8 Hz, H-3′,5′), 6.39 (1H, d, J =
2.0 Hz, H-8), 6.19 (1H, d, J = 2.0 Hz, H-6), 5.26 (1H, d, J =
7.2 Hz, H-1″), 3.69 (1H, dd, J = 11.9, 2.3 Hz, H-6″a), 3.53
(1H, dd, J = 12.0, 5.5 Hz, H-6″b), 3.43 (1H, m, H-2″), 3.42
(1H, m, H-3″), 3.30 (1H, m, H-4″), 3.20 (1H, ddd, J = 9.7,
5.5, 2.3 Hz, H-5″); 13C NMR (100 MHz, CD3OD) δ:
179.53 (s, C-4), 166.21 (s, C-7), 163.11 (s, C-5), 161.61 (s,
C-4′), 159.07 (s, C-2), 158.55 (s, C-9), 135.47 (s, C-3),
132.31 (d, C-2′,6′), 122.82 (s, C-1′), 116.10 (d, C-3′,5′),
105.71 (s, C-10), 104.09 (d, C-1″), 99.96 (d, C-6), 94.81 (d,
C-8), 78.46 (d, C-5″), 78.07 (d, C-3″), 75.77 (d, C-2″),
71.38 (d, C-4″), 62.65 (t, C-6″).
Isoquercetin (quercetin 3-O-β-D-glucopyranoside, 11):
Yellow amorphous solid; [α]D
25 −24.6° (c = 0.02, MeOH);
1H NMR (400 MHz, CD3OD) δ: 7.71 (1H, d, J = 2.2 Hz,
H-2′), 7.59 (1H, dd, J = 8.4, 2.0 Hz, H-6′), 6.86 (1H, d, J =
8.5 Hz, H-5′), 6.36 (1H, br s, H-8), 6.18 (1H, d, J = 1.8 Hz,
H-6), 5.23 (1H, d, J = 7.5 Hz, H-1″), 3.71 (1H, dd, J = 11.9,
2.3 Hz, H-6″a), 3.57 (1H, dd, J = 11.9, 5.2 Hz, H-6″b),
3.47 (1H, t, J = 8.2 Hz, H-2″), 3.42 (1H, t, J = 8.6 Hz, H-
3″), 3.34 (1H, m, H-4″), 3.21 (1H, m, H-5″);
Trifolin (kaempferol 3-O-β-D-galactopyranoside, 12):
Yellow amorphous solid; [α]D
25 −32.4° (c = 0.11, MeOH);
1H NMR (400 MHz, CD3OD) δ: 8.09 (2H, d, J = 8.7 Hz,
H-2′,6′), 6.88 (2H, d, J = 8.7 Hz, H-3′,5′), 6.40 (1H, d, J
= 1.5 Hz, H-8), 6.20 (1H, d, J = 1.9 Hz, H-6), 5.14 (1H, d,
J = 7.8 Hz, H-1″), 3.81 (1H, d, J = 3.5 Hz, H-4″), 3.78
(1H, dd, J = 9.6, 7.9 Hz, H-2″), 3.62 (1H, dd, J = 11.1,
6.1 Hz, H-6″a), 3.52 (1H, m, H-3″), 3.51 (1H, m, H-6″
b), 3.43 (1H, t, J = 6.1 Hz, H-5″); 13C NMR (100 MHz,
CD3OD) δ: 166.40 (s, C-7), 163.10 (s, C-5), 161.65 (s, C-
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4′), 159.04 (s, C-2), 158.57 (s, C-9), 135.59 (s, C-3),
132.40 (d, C-2′,6′), 122.73 (s, C-1′), 116.14 (d, C-3′,5′),
105.61 (s, C-10), 105.00 (d, C-1″), 100.02 (d, C-6), 94.85
(d, C-8), 77.17 (d, C-5″), 75.07 (d, C-3″), 73.05 (d, C-
2″), 70.05 (d, C-4″), 62.01 (t, C-6″).
Kaempferol 3-O-β-D-xylopyranoside (13): Yellow
amorphous solid; [α]D
25 −63.8° (c = 0.18, MeOH); 1H
NMR (400 MHz, CD3OD) δ: 8.03 (2H, d, J = 8.8 Hz, H-
2′,6′), 6.88 (2H, d, J = 8.8 Hz, H-3′,5′), 6.40 (1H, d, J =
2.1 Hz, H-8), 6.20 (1H, d, J = 2.0 Hz, H-6), 5.19 (1H, d, J
= 7.2 Hz, H-1″), 3.77 (1H, dd, J = 11.5, 5.1 Hz, H-5″a),
3.48 (1H, m, H-2″), 3.48 (1H, m, H-4″), 3.40 (1H, t, J =
8.6 Hz, H-3″), 3.11 (1H, dd, J = 11.6, 9.6 Hz, H-5″b);
13C NMR (100 MHz, CD3OD) δ: 179.4 (s, C-4), 166.1 (s,
C-7), 163.0 (s, C-5), 161.6 (s, C-4′), 158.9 (s, C-2), 158.4
(s, C-9), 135.3 (s, C-3), 132.2 (d, C-2′,6′), 122.6 (s, C-1′),
116.1 (d, C-3′,5′), 105.6 (s, C-10), 104.6 (d, C-1″), 99.9
(d, C-6), 94.8 (d, C-8), 77.5 (d, C-3″), 75.3 (d, C-2″),
71.0 (d, C-4″), 67.2 (t, C-5″).
Reinutrin (quercetin 3-O-β-xylopyranoside, 14): Brown
amorphous solid; 1H NMR (400 MHz, CD3OD) δ: 7.60
(1H, m, H-2′), 7.59 (1H, m, H-6′), 6.85 (1H, d, J = 8.4 Hz,
H-5′), 6.39 (1H, br s, H-8), 6.20 (1H, br s, H-6), 5.18 (1H,
d, J = 7.2 Hz, H-1″), 3.78 (1H, dd, J = 11.6, 5.2 Hz, H-5″a),
3.51 (1H, m, H-2″), 3.50 (1H, m, H-4″), 3.39 (1H, t, J =
8.6 Hz, H-5″b), 3.09 (1H, dd, J = 11.7, 9.6 Hz, H-5″b). 13C
NMR (100 MHz, CD3OD) δ: 166.6 (C-7), 163.1 (C-5),
159.8 (C-2), 158.5 (C-9), 149.9 (C-4′), 146.1 (C-3′), 135.4
(C-3), 123.3 (C-6′), 123.1 (C-1′), 117.2 (C-2′), 116.0 (C-
5′), 106.3 (C-10), 105.5 (C-1″), 100.1 (C-6), 94.8 (C-8),
77.6 (C-3″), 75.3 (C-2″), 71.0 (C-4″), 67.3 (C-5″).
Juglanin (kaempferol 3-O-α-L-arabinofuranoside, 15):
Yellow amorphous solid; [αD
25] −112.9° (c = 0.16, MeOH);
1H NMR (400 MHz, CD3OD) δ: 7.96 (2H, d, J = 8.5 Hz,
H-2′,6′), 6.93 (2H, d, J = 8.5 Hz, H-3′,5′), 6.41 (1H, d, J
= 2.1 Hz, H-8), 6.21 (1H, d, J = 2.1 Hz, H-6), 5.49 (1H, s,
H-1″), 4.33 (1H, d, J = 3.0 Hz, H-2″), 3.91 (1H, dd, J =
5.2, 3.1 Hz, H-3″), 3.80 (1H, dd, J = 9.3, 4.7 Hz, H-4″),
3.49 (2H, d, J = 4.2 Hz, H-5″); 13C NMR (100 MHz,
CD3OD) δ: 179.95 (s, C-4), 166.04 (s, C-7), 163.12 (s, C-
5), 161.60 (s, C-4′), 159.42 (s, C-2), 158.59 (s, C-9),
134.96 (s, C-3), 132.02 (d, C-2′,6′), 122.80 (s, C-1′),
116.54 (d, C-3′,5′), 109.65 (d, C-1″), 105.69 (s, C-10),
99.90 (d, C-6), 94.82 (d, C-8), 88.03 (d, C-4″), 83.39 (d,
C-2″), 78.66 (d, C-3″), 62.55 (t, C-5″).
Avicularin (quercetin 3-O-α-arabinofuranoside, 16):
Orange amorphous solid; 1H NMR (400 MHz, CD3OD)
δ: 7.53 (1H, d, J = 2.1 Hz, H-2′), 7.50 (1H, dd, J = 8.3,
2.1 Hz, H-6′), 6.91 (1H, d, J = 8.3 Hz, H-5′), 6.40 (1H, d,
J = 2.1 Hz, H-8), 6.22 (1H, d, J = 1.9 Hz, H-6), 5.47 (1H,
s, H-1″), 4.33 (1H, s, H-2″), 3.92 (1H, dd, J = 5.2, 2.9 Hz,
H-3″), 3.86 (1H, m, H-4″), 3.50 (2H, m, H-5″); 13C
NMR (100 MHz, CD3OD) δ: 180.02 (s, C-4), 166.20 (s,
C-7), 163.12 (s, C-5), 159.38 (s, C-2), 158.62 (s, C-9),
149.90 (s, C-4′), 146.41 (s, C-3′), 134.94 (s, C-3), 123.13
(s, C-1′), 122.99 (d, C-6′), 116.86 (d, C-2′), 116.47 (d, C-
5′), 109.55 (d, C-1″), 105.62 (s, C-10), 99.95 (d, C-6),
94.83 (d, C-8), 88.05 (d, C-4″), 83.35 (d, C-2″), 78.73 (d,
C-3″), 62.57 (t, C-5″).
Juglalin (kaempferol 3-O-α-arabinopyranoside, 17):
Yellow amorphous solid; 1H NMR (400 MHz, CD3OD)
δ: 8.06 (2H, d, J = 8.6 Hz, H-2′,6′), 6.89 (2H, d, J =
8.5 Hz, H-3′,5′), 6.40 (1H, d, J = 2.0 Hz, H-8), 6.20 (1H,
d, J = 1.9 Hz, H-6), 5.14 (1H, d, J = 6.4 Hz, H-1″), 3.89
(1H, dd, J = 8.2, 6.3 Hz, H-2″), 3.78 (1H, m, H-4″), 3.77
(1H, m, H-5″a), 3.63 (1H, m, H-3″), 3.40 (1H, dd, J =
13.5, 3.1 Hz, H-5″b); 13C NMR (100 MHz, CD3OD) δ:
179.58 (s, C-4), 166.42 (s, C-7), 163.11 (s, C-5), 161.68
(s, C-4′), 158.84 (s, C-2), 158.53 (s, C-9), 135.58 (s, C-3),
132.30 (d, C-2′,6′), 122.66 (s, C-1′), 116.29 (d, C-3′,5′),
105.60 (s, C-10), 104.41 (d, C-1″), 100.04 (d, C-6), 94.86
(d, C-8), 74.04 (d, C-3″), 72.80 (d, C-2″), 68.97 (d, C-
4″), 66.78 (t, C-5″).
Benzyl 2-O-β-glucopyranosyl-2,6-hydroxybenzoate (18):
Yellowish oil; [αD
25] −14.8° (c = 0.047, MeOH); 1H NMR
(400 MHz, CD3OD) δ: 7.50 (2H, d, J = 7.4 Hz, H-2′,6′),
7.38 (2H, t, J = 7.4 Hz, H-3′,5′), 7.32 (1H, t, J = 7.1 Hz, H-
4′), 7.27 (1H, t, J = 8.3 Hz, H-4), 6.75 (1H, d, J = 8.4 Hz, H-
3), 6.59 (1H, d, J = 8.4 Hz, H-5), 5.38 (2H, s, H-7′), 4.94
(1H, d, J = 6.4 Hz, H-1″), 3.86 (1H, br d, J = 12.2 Hz, H-6″
a), 3.66 (1H, dd, J = 12.2, 5.7 Hz, H-6″b), 3.43 (1H, m, H-
5″), 3.39 (1H, m, H-2″), 3.39 (1H, m, H-3″), 3.34 (1 H, m,
H-4″); 13C NMR (100 MHz, CD3OD) δ: 170.00 (s, C-7),
159.80 (s, C-6), 158.25 (s, C-2), 137.40 (s, C-1′), 134.04 (d,
C-4), 129.55 (d, C-3′,5′), 129.22 (2×, d, C-2′,6′, C-4′),
111.57 (d, C-5), 110.87 (s, C-1), 107.79 (d, C-3), 102.75 (d,
C-1″), 78.34 (d, C-3″), 77.99 (d, C-5″), 74.93 (d, C-2″),
71.25 (d, C-4″), 68.19 (t, C-7′), 62.54 (t, C-6″).
Byzantionoside B (19): Orange amorphous solid; 1H
NMR (400 MHz, CD3OD) δ: 5.81 (1H, s, H-4), 4.33 (1H,
d, J = 8.0 Hz, H-1′), 3.87 (1H, m, H-9), 3.86 (1H, m, H-6′
a), 3.65 (1H, m, H-6′b), 3.35 (1H, m, H-3′), 3.26 (1H, m,
H-4′), 3.26 (1H, m, H-5′), 3.14 (1H, dd, J = 9.1, 7.8 Hz, H-
2′), 2.47 (1H, d, J = 17.4 Hz, H-2), 2.05 (3H, d, J = 1.3 Hz,
H-13), 1.98 (1H, m, H-6), 1.97 (1H, m, H-2), 1.95 (1H, m,
H-7), 1.63 (2H, m, H-8), 1.51 (1H, m, H-7), 1.19 (3H, d, J
= 6.2 Hz, H-10), 1.10 (3H, s, H-12), 1.01 (3H, s, H-11); 13C
NMR (100 MHz, CD3OD) δ: 202.48 (s, C-3), 170.17 (s, C-
5), 125.41 (d, C-4), 102.15 (d, C-1′), 78.20 (d, C-3′), 77.93
(d, C-5′), 75.54 (d, C-9), 75.20 (d, C-2′), 71.88 (d, C-4′),
62.95 (t, C-6′), 52.43 (d, C-6), 48.12 (t, C-2), 37.84 (t, C-8),
37.36 (s, C-1), 29.10 (q, C-11), 27.56 (q, C-12), 26.87 (t, C-
7), 25.01 (q, C-13), 19.91 (q, C-10).
Cell and virus culture
African green monkey kidney cells (Vero, ATCC CCL-
81) were obtained from the American Type Culture Col-
lection (ATCC, Manassas, USA). The Vero cell lines
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were grown in Eagle’s minimal essential medium (MEM)
(Mediatech Cellgro, VA) supplemented with 10% fetal
bovine serum (FBS; Hyclone, Logan, USA), penicillin
(100 IU) and streptomycin (100 μg mL−1) (Mediatech
Cellgro®). Cells were cultured in a humidified atmos-
phere at 37 °C in 5% CO2. The maintenance medium
was MEM supplemented with TPCK trypsin (2 μg mL
−1), glucose (2 mg mL−1), bovine serum albumin
(1 mg mL−1), penicillin (100 IU) and streptomycin
(100 μg mL−1). HSV-1 (ATCC VR-733) stocks were
propagated in Vero cells. Viruses were stored at −80 °C
before further analysis. The virus titer was determined
by plaque assay [30].
Cytotoxicity assay
Exponentially growing Vero cells were plated at a
density of 15 × 103 cells per well in 96-well micro-
plates (Costar, Corning Inc.) in 100 μL of culture
medium and were allowed to adhere before treatment.
Then, 100 μL of increasing concentrations of extract
dissolved in aqueous DMSO (Sigma–Aldrich) were
added. The final solvent concentration in the culture
medium was maintained at 0.25% (v/v) to avoid solv-
ent toxicity. The Vero cells were incubated for 72 h
in the absence or in the presence of extracts. Cyto-
toxicity was assessed using the resazurin reduction
test [31]. Fluorescence was measured using an auto-
mated 96-well Fluoroskan Ascent Fl TM plate reader
(Labsystems) at excitation and emission wavelengths
of 530 and 590 nm, respectively. Fluorescence was
proportional to the cellular metabolic activity in each
well. Cytotoxicity was measured as the concentration
of extract inhibiting cell growth by 50% (IC50).
Antiviral activity of extracts, fractions and compounds
against HSV-1
Plaque reduction assays were performed with mono-
layer cultures of Vero cells in 24-well culture plates
as described by Kock et al. with some modifications
[32]. Briefly, the cell monolayer was infected with the
virus (30 pfu/well) and incubated at 37 °C with 5%
CO2 for one hour. The infected cell monolayer was
then washed with PBS and overlaid with an overlap-
ping solution (maintenance medium containing 1%
methylcellulose and various concentrations of the in-
dicated compounds). After a 72-hour incubation at
37 °C, the cell monolayer was fixed with 5% parafor-
maldehyde and stained with 0.8% crystal violet. The
lysis plaques were counted and the percentage of in-
hibition was calculated as [(Pcontrol – Psample)/Pcon-
trol] × 100, where Pcontrol and Psample refer to the lysis
plaque number in the absence and in the presence of
the extract, fraction or compound, respectively. The
effective concentration inhibiting 50% of the lysis
plaques induced by HSV-1 (EC50) was also calculated
from dose-response curves.
Determination of the mode of antiviral activity
In order to determine the mode of antiviral activity,
Vero cells and HSV-1 were incubated with various
samples including crude extracts, fractions and com-
pounds at different stages during viral infection [32].
Acyclovir was used as a positive control. To evaluate
the protection mode, Vero cells were first pre-
treated one hour at 37 °C with samples before infec-
tion with HSV-1. Vero cells and viruses were also
incubated for one hour at 37 °C together with sam-
ples during the absorption period. Moreover, the ef-
fect of the sample was tested during the replication
period by adding samples to the overlay medium
after infection. Finally, to determine the direct mode
of antiviral activity, viruses were incubated with the
sample for one hour at 37 °C before infection of
Vero cells with HSV-1.
Statistical analysis
All experiments were performed in triplicates for HSV-
1. A one-way ANOVA with a Tukey’s multiple compari-
son test was performed to compare extracts with the
negative control for the antiviral assay. The statistical
significance was set at p < 0.05.
Results
The aim of this study was to evaluate the anti-HSV-1 ac-
tivity of a plant used by the Native Americans in trad-
itional medicine. The plant was selected based on its
potential use to treat herpes labialis symptoms such as
cold sores, fever and pain [13].
Extraction yield and cytotoxicity of the extracts on Vero
cells
Leaves were extracted by decoction or infusion, using
water, water/ethanol 1:1 and ethanol as solvent, to
obtain extracts similar to those used by Native Amer-
icans. Table 1 presents yields of the six extracts
expressed as a percentage of the weight of the crude
extract to the raw material. The extraction yields
range from 12 to 37%. Regardless of the method, the
highest yields were obtained with aqueous systems
(30 to 37%) and the lowest ones with pure ethanol
(12 to 18%). The decoction method using pure water
or ethanol as solvents was more efficient in compari-
son with the infusion method. In contrast, both
methods were relatively similar using a water/ethanol
1:1 solvent. On the other hand, the effect of extracts
on Vero cell growth was evaluated to ensure that they
were not cytotoxic to cells before testing the antiviral
activity. Vero cells were incubated in the presence or
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in the absence of a growing concentration of extract
over three days. The results (Table 1), expressed as
the concentration inhibiting 50% of cell growth (IC50),
show that all leaf extracts were not cytotoxic at con-
centration below 100 μg mL−1 except for the ethanol
extract (IC50 = 88 μg mL
−1).
Antiviral activity of the extracts against herpes simplex
virus type-1
The antiviral activity of all leaf extracts from C.
canadensis was evaluated against herpes simplex
virus type-1 (HSV-1). Vero cells and viruses were in-
cubated with extracts at different stages of the viral
infection to determine the mode of antiviral activity
such as protection, absorption, replication and direct
modes [32]. Acyclovir, an antiviral agent inhibiting
the replication of HSV-1, was used as a positive con-
trol. At a concentration of 0.75 μg mL−1, acyclovir
completely protects Vero cells against infection (data
not shown). Firstly, results presented in Table 2
show that Vero cells pre-treatment for one hour
with all extracts (100 μg mL−1) did not protect them
against infection (protection mode). However, the
extracts inhibited 90 to 100% of the lysis plaque for-
mation induced by HSV-1 when viruses were pre-
treated with the extracts (direct mode) or when Vero
cells and viruses were incubated together with the
extracts (absorption mode). Moreover, the extracts of
C. canadensis leaves protected Vero cells during the
replication period with an inhibition of the lysis
plaque ranging from 69 to 94% at a concentration of
100 μg mL−1. The effects of the ethanol extract ob-
tained using infusion were not tested during the rep-
lication period due to the cytotoxicity.
The effective concentration inhibiting 50% of lysis
plaques induced by HSV-1 (EC50) was determined in
order to identify the most active extracts from C.
canadensis. Growing concentrations of extracts ran-
ging from 1.56 to 100 μg mL−1 were tested at differ-
ent stages of viral infection as previously described.
Extracts showing an EC50 higher than 50 μg mL
−1
were considered to be inactive. All extracts were in-
active in protection mode as well as during the repli-
cation period with EC50 > 50 μg mL
−1. On absorption
mode, the most active extracts were obtained using
decoction method with water as solvent with an EC50
of 9 ± 1 μg mL−1 and the infusion method with water/
ethanol 1:1 as solvent with an EC50 of 9 ± 3 μg mL
−1.
On direct mode, both extraction methods using water
or water/ethanol 1:1 as solvent were relatively similar
with EC50 ranging from 11 to 17 μg mL
−1.
Bioassay-guided fractionation
A bioassay-guided fractionation was undertaken in
order to identify the bioactive components of the ex-
tract. For this, a large scale decoction was accom-
plished from fresh C. canadensis leaves. The crude
extract was then partitioned by liquid-liquid separ-
ation between water, n-butanol, and chloroform. The
resulting fractions were screened for their anti-HSV-1
Table 2 Anti-HSV-1 activities of leaf extracts from C. canadensis
Extraction Solvent Bioactivity for each mode of antiviral activitya
Protectionb Absorptionc Replicationd Directe
Decoction H2O NA 100 (9 ± 1) 69 ± 11 (> 50) 100 (17 ± 6)
H2O/EtOH 1:1 NA 99 ± 2 (31 ± 5) 94 ± 4 (> 50) 100 (14 ± 4)
EtOH NA 90 ± 0 (44 ± 8) 91 ± 16 (> 50) 100 (22 ± 3)
Infusion H2O NA 99 ± 2 (17 ± 2) 85 ± 7 (> 50) 100 (14 ± 3)
H2O/EtOH 1:1 NA 98 ± 4 (9 ± 3) 82 ± 10 (> 50) 100 (11 ± 2)
EtOH NA 100 (40 ± 5) Tx 100 (28 ± 6)
NA Inhibition of lysis plaques < 50% was considered not active, Tx Cytotoxic against Vero cells at 100 μg mL−1
aInhibitory percentage of lysis plaque induced by HSV-1 at a sample concentration of 100 μg mL−1 (top row), and effective concentration (μg mL−1) inhibiting 50%
(EC50) of lysis plaque (bottom row; in parentheses). Acyclovir was used as positive control with 100% inhibition of lysis plaques at a concentration of 0.75 μg mL
−1
bVero cells were pretreated with compounds prior infection
cVero cells and viruses were incubated together with compounds during the absorption period
dCompounds were added after absorption and during the replication period
eViruses were incubated directly with compounds prior infection of Vero cells
Table 1 Extraction yield (%) and cytotoxicity on Vero cells of
extracts from leaves of C. canadensis





Decoction H2O 36.5 > 100
H2O/EtOH 1:1 34.1 > 100
EtOH 18.0 > 100
Infusion H2O 30.1 > 100
H2O/EtOH 1:1 34.3 > 100
EtOH 12.2 88 ± 18
aPercentage of weight of crude extract to raw material (10 g)
bConcentration (μg mL−1) inhibiting 50% of Vero cells growth
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activity. The n-BuOH fraction showed a complete in-
hibition of lysis plaques at a concentration of
50 μg mL−1 in both the absorption and direct modes
and was thus chosen for further fractionations (Fig. 1).
Open column chromatography on Diaion® stationary
phase was carried out with a gradient of water/metha-
nol as the eluent. The six resulting fractions (F1–F6)
were tested against HSV-1 (Fig. 1). Fractions F3 and
F4 were the most active toward both modes of activ-
ity when tested at 25 μg mL−1. Their HPLC profiles
(Fig. 2) were almost identical, therefore the most
abundant fraction (F4) was chosen for the next step.
Silica gel was selected as an adsorbent for low-
pressure liquid chromatography using a gradient of
dichloromethane and methanol as the eluent. Seven
fractions were obtained (F4.1-F4.7), analyzed by HPLC
(Fig. 3), and evaluated for their antiviral activity
(Fig. 1). The most active fractions (F4.4 and F4.5)
were submitted to preparative HPLC yielding seven
hydrolysable tannins (1–7). On the other hand, Frac-
tion F5 was shown to be barely active toward HSV-1,
either in the direct or absorption modes (Fig. 1).
However, according to TLC, this fraction was rich in
secondary metabolites and was thus further purified
by silica gel chromatographies followed by reversed-
phase preparative HPLC yielding 12 other compounds
(8–19).
The structures of all the isolated compounds were
established on the basis of extensive spectroscopic ana-
lyses, including 1D and 2D NMR (1H–1H COSY, HSQC,
and HMBC), and by comparison of their respective
spectral data with those reported in the literature (Fig. 4).
They were identified as: 1,6-di-O-galloyl-β-D-glucopyra-
nose (1), 1,2,3-tri-O-galloyl-β-D-glucopyranose (2), 1,2,6-
tri-O-galloyl-β-D-glucopyranose (3), 1,2,3,6-tetra-O-gal-
loyl-β-D-glucopyranose (4), 1,2,3,4,6-penta-O-galloyl-β-
D-glucopyranose (5), tellimagrandin I (6), tellimagrandin
II (7), ethyl gallate (8), caffeic acid (9), astragalin (10),
isoquercetin (11), trifolin (12), kaempferol 3-O-β-D-xylo-
pyranoside (13), reinutrin (14), juglanin (15), avicularin
(16), juglalin (17), benzyl 2-O-β-glucopyranosyl-2,6-
hydroxybenzoate (18) and byzantionoside B (19).
Antiviral activity of the isolated compounds
Hydrolysable tannins (4–7) isolated from the most active
fraction (F4) were tested for their anti-HSV-1 activity
using a similar protocol as previously described for the
extracts and fractions. Growing concentrations of com-
pounds, ranging from 1.56 to 25 μg mL−1, were tested in
order to evaluate the effective concentration inhibiting
50% of lysis plaques induced by HSV-1 (EC50). The re-
sults presented in Table 3 showed that the most active
compound was tellimagrandin I (6) with EC50 of 5.0 ±
0.2 and 2.6 ± 0.1 μM for the absorption and direct
modes, respectively. The other compounds showed EC50
ranging between 7 and 12 μM.
Discussion
C. canadensis was used in Native American trad-
itional medicine to treat possible viral infections. The
results showed that the hydroalcoholic extract ob-
tained from the infusion of C. canadensis acts directly
on the virus and also inhibits its absorption by host
cells. Some studies aiming to determine the chemical
composition of C. canadensis showed the presence of
iridoids, but no antiviral activity for these compounds
was reported [33]. Moreover, seven other iridoids
were tested by Bermejo and co-workers against HSV-
1 and none of these compounds were found active
against this virus [34]. On the other hand, some fla-
vonoids, previously described in C. canadensis extracts
[35], are also known for their antiviral activity against
Fig. 1 Antiviral activities against HSV-1 of crude extract and fractions obtained from C. canadensis. Extract and fractions were incubated with
viruses prior infection (direct mode) or together with Vero cells and viruses during infection (absorption mode). The results are expressed as the
percentage of inhibition of the lysis plaques at the indicated concentration
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Fig. 2 HPLC profiles of fractions F1-F6. In parentheses are the masses obtained after column chromatography. Column: Zorbax Eclipse XDB-C18
column (4.6 × 250 mm, 5 μm); Injection: 10μL at 10 mg mL−1; Éluent: H2O + 0.1% HCOOH and CH3CN + 0.1% HCOOH; Program: 5% held for 5 min,
5% to 20% in 20 min, 20% to 90% in 5 min, 90% held for 10 min; Flow: 1 mL min−1; Detection: UV 254 ± 50 nm
Fig. 3 HPLC profiles of fractions F4.1-F4.7. In parentheses are the masses obtained after column chromatography. Column: Zorbax Eclipse XDB-C18
column (4.6 × 250 mm, 5 μm); Injection: 10μL at 10 mg mL−1; Eluent: H2O + 0.1% HCOOH and CH3CN + 0.1% HCOOH; Program: 5% held for 5 min,
5% to 20% in 20 min, 20% to 90% in 5 min, 90% held for 10 min; Flow: 1 mL min−1; Detection: UV 254 ± 50 nm
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HSV-1 [36]. For instance, quercetin is known for its viru-
cidal action and its direct inactivation of HSV-1 [37].
However, in the present study, flavonoids were identified
from scarcely active fractions. After intensive bioassay-
guided fractionation, hydrolysable tannins were finally
identified as good candidate compounds responsible for
the bioactivity. It is noteworthy that the activity was higher
in the direct mode rather than in the absorption mode.
These results are consistent with those obtained for the
same compounds in other works [38–41] with the excep-
tion of tellimagrandin I (6), which has been reported more
active in another study with an EC50 of 0.046 μM [42].
However, this difference could be explained by the use of
different host cell lines and virus strains.
Fig. 4 Structures of the isolated compounds from Cornus canadensis
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Conclusions
C. canadensis, a plant used by Native Americans in
traditional medicine to treat possible viral infection,
was investigated for its anti-HSV-1 activity. The re-
sults reported in this study showed that the hydroal-
coholic extract obtained from leaves of C. canadensis
acts directly on HSV-1, but also inhibits the absorp-
tion of the virus by the host cells. Hydrolysable tan-
nins were isolated from the most active fraction and
shown to be good candidate compounds responsible
for the anti-HSV-1 activity. In a near future, the
mechanism of action of the extract and of the bio-
active compounds will be determined.
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